All In Biotech

Free tool

FAERS Monitor: Symlin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021332 or its brand name (Symlin, Pramlintide Acetate). Reports on generic versions are filed under their own applications.

Reports

102

Serious

51

50% of reports

Hospitalization

25

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased15
  • acute kidney injury11
  • chronic kidney disease11
  • nausea9
  • dyspnoea8
  • fatigue8
  • hypertension7
  • renal failure7
  • weight decreased7
  • chest pain6
  • diarrhoea6
  • drug ineffective6
  • osteoarthritis6
  • weight increased6
  • back pain5

Reports by year received

View as table
YearReports
20061
20071
20085
20101
20111
20129
20138
20148
201511
201613
20175
20189
201910
20208
20214
20223
20233
20242

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal1129.917.1280
osteoarthritisSignal629.213.4137
blood glucose increasedSignal1516.410.3204
acute kidney injurySignal1114.88.5129
renal failureSignal710.95.354
hypertensionSignal76.83.329
chest painSignal66.73.124
weight increasedSignal65.52.518
weight decreasedSignal75.22.520
back painSignal54.41.910
dyspnoeaSignal82.91.58
nauseaSignal92.31.36
fatigue82.11.14
diarrhoea61.90.92
drug ineffective60.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.